# MajesTEC-7 (NCT05552222)

> A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05552222
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Teclistamab; Daratumumab; Lenalidomide; Dexamethasone; Talquetamab
- Enrollment: 1590
- Primary outcome: Progression Free Survival (PFS)
- Primary outcome: 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)

## Commentary we found

- YouTube: 19
- X threads: 9
- Podcasts: 8

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=majestec-7-nct05552222

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05552222", "email": "<work email>"}; the inbox owner confirms by the emailed link.